Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 42

Results For "MP"

9882 News Found

Arkema grants technology license to Seqens to manufacture PEKK for sale in medical implantable applications
News | June 25, 2024

Arkema grants technology license to Seqens to manufacture PEKK for sale in medical implantable applications

PEKK is a high-performance polymer family used in aerospace and other demanding markets


USFDA completes audit of contract manufacturing facility of Jubilant Pharmova Montreal unit
Drug Approval | June 19, 2024

USFDA completes audit of contract manufacturing facility of Jubilant Pharmova Montreal unit

The USFDA has issued 15 observations pursuant to the completion of audit. JHSGP will submit an action plan on the observations


Boehringer Ingelheim’s survodutide demonstrates breakthrough improvement in liver fibrosis
Clinical Trials | June 09, 2024

Boehringer Ingelheim’s survodutide demonstrates breakthrough improvement in liver fibrosis

New data on the secondary endpoint shows up to 52.3% of adults with fibrosis stages F1, F2 and F3 had improvement in fibrosis due to MASH


Lupin completes acquisition of two brands from Sanofi in Europe and Canada
News | June 08, 2024

Lupin completes acquisition of two brands from Sanofi in Europe and Canada

The transaction aligns with Lupin's strategy to grow its global presence in Specialty areas


Merck completes € 180 million investment to expand Schnelldorf Distribution Center
Supply Chain | June 07, 2024

Merck completes € 180 million investment to expand Schnelldorf Distribution Center

Merck has opened its newly expanded Life Science distribution center in Schnelldorf, Germany


Jemperli trial continues to show positive results for deficient (dMMR) rectal cancer
Clinical Trials | June 06, 2024

Jemperli trial continues to show positive results for deficient (dMMR) rectal cancer

Updated analysis from Memorial Sloan Kettering Cancer Center presented at ASCO 2024 has expanded to 42 patients with clinical complete response


AstraZeneca completes acquisition of Fusion Pharmaceuticals
News | June 05, 2024

AstraZeneca completes acquisition of Fusion Pharmaceuticals

This acquisition complements AstraZeneca’s leading oncology portfolio with the addition of the Fusion pipeline of RCs


Bristol Myers Squibb announces Opdivo Plus Yervoy (ipilimumab) improved overall survival for patients with unresectable hepatocellular carcinoma
Clinical Trials | June 05, 2024

Bristol Myers Squibb announces Opdivo Plus Yervoy (ipilimumab) improved overall survival for patients with unresectable hepatocellular carcinoma

Dual immunotherapy combination of Opdivo plus Yervoy demonstrated improved survival benefit compared to lenvatinib or sorafenib in this patient population


Pfizer’s ADCETRIS regimen produces clinically meaningful improvement in overall survival in patients with DLBCL
Clinical Trials | June 04, 2024

Pfizer’s ADCETRIS regimen produces clinically meaningful improvement in overall survival in patients with DLBCL

Third Phase 3 trial in third type of lymphoma to show improvement in overall survival with an ADCETRIS-containing regimen


Takeda and Pfizer announce results from Positive Phase 3 HD21 trial of additional ADCETRIS combination in frontline hodgkin lymphoma
News | June 03, 2024

Takeda and Pfizer announce results from Positive Phase 3 HD21 trial of additional ADCETRIS combination in frontline hodgkin lymphoma

The HD21 study adds to the body of evidence supporting ADCETRIS as a backbone agent in the treatment of specific lymphomas